Novartis is a major global biopharmaceutical company. It lobbies Congress on federal funding and budgets for health agencies like the FDA, drug pricing and patient assistance programs such as the 340B drug discount program, Medicare and Medicaid prescription policies, trade issues, and patent/copyright matters tied to medicines. Filings show six disclosures totaling about $10.3 million, most recently in March 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
COURTNEY LEE-ASHLEY
The latest disclosures for this client.
NOVARTIS
Q3NOVARTIS
Q2The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
These contribution items line up to this client through the same lobbying firm and reporting window, and when available the same contributing lobbyist.
NOVARTIS
COURTNEY PIRON
NOVARTIS
JOSEPH MCGOWAN
NOVARTIS
mr THOMAS ANDREW SUTER
NOVARTIS
SARAH DURR
NOVARTIS
TAYLOR BOOTH
NOVARTIS
LEO A FARBER
NOVARTIS
PETER STEHOUWER
NOVARTIS
NOVARTIS
Q1NOVARTIS
3ANOVARTIS
2ANOVARTIS
Q4NOVARTIS
Q3NOVARTIS
Q2NOVARTIS
Q1